Hims adds cancer detection test to Labs product

Hims & Hers will add Galleri, a cancer detection test made by Grail, to its offerings as it works to expand its Labs product.

Hims said Wednesday that it would add the blood test, which says it detects signals for over 50 types of cancer before symptoms appear, to its portfolio. It comes at a $250 discount to the Galleri list price, which is $949, but it’s available only to Labs subscribers.

Hims rose by as much as 5% early trading following the announcement after several days of declines.

Hims launched its lab analysis product, which is a central part of its upcoming Super Bowl commercial, in November. The advertisement unveiled last week alluded to a cancer detection product. Grail announced in October that it raised $325 million from several investors, including Hims. The company did not give specifics of its business relationship with Grail or how the investment plays into it.

Hims’ labs product initially marketed two tiers: a base plan that costs $199 per year or an advanced plan for $499. It now offers a single plan at $349 a year. It’s one of several product expansions the company has announced as it pivots focus away from weight-loss treatments.

Grail has sold roughly 185,000 Galleri tests as of the end of 2025, according to a recent presentation the company gave at the JPMorgan Healthcare Conference in San Francisco. The Galleri tests brought in between $138 million and $139 million in revenue last year, up from $109 million in 2024.

Grail announced Thursday that it filed for Food and Drug Administration approval of its Galleri test. The test has been available commercially since 2021, but approval from the FDA could position it to be covered by major insurers.

The test has been available through partners like Quest Diagnostics and Function Health, a lab analysis startup offering a similar product to Hims, which announced it would offer Galleri tests in December.

Correction: An earlier version of this story provided outdated Hims Labs' pricing tiers.